Population Pharmacokinetics and Pharmacodynamics of Doxorubicin and Cyclophosphamide in Breast Cancer Patients

This publication has 35 references indexed in Scilit:

• Second consensus on medical treatment of metastatic breast cancer
  Annals of Oncology, 2006
• High exposures to bioactivated cyclophosphamide are related to the occurrence of veno-occlusive disease of the liver following high-dose chemotherapy
  British Journal of Cancer, 2006
• Doxorubicin pharmacokinetics is correlated to the effect of induction therapy in children with acute myeloid leukemia
  Anti-Cancer Drugs, 2006
• Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
  New England Journal of Medicine, 2005
• Phase III Randomized Trial of Doxorubicin and Docetaxel Versus Doxorubicin and Cyclophosphamide As Primary Medical Therapy in Women With Breast Cancer: An Anglo-Celtic Cooperative Oncology Group Study
  Journal of Clinical Oncology, 2005
• Model Describing the Relationship Between Pharmacokinetics and Hematologic Toxicity of the Epirubicin-Docetaxel Regimen in Breast Cancer Patients
  Journal of Clinical Oncology, 2005
• Clinical Pharmacokinetics of Cyclophosphamide
  Clinical Pharmacokinetics, 2005
• Factors affecting pharmacokinetic variability following doxorubicin and docetaxel-based therapy
  European Journal of Cancer, 2004
• Docetaxel and Doxorubicin Compared With Doxorubicin and Cyclophosphamide as First-Line Chemotherapy for Metastatic Breast Cancer: Results of a Randomized, Multicenter, Phase III Trial
  Journal of Clinical Oncology, 2003
• Population pharmacokinetics of doxorubicin, etoposide and ifosfamide in small cell lung cancer patients: results of a multicentre study
  British Journal of Clinical Pharmacology, 2000